| Ytd | 35.36% | |
| 1y | -11.39% |
| Open | 4.16 | Prev Close | 4.13 | Low | 4.15 | High | 4.85 | Mkt Cap | 143.73M |
| Vol | 611.91K | Avg Vol | 285.18K | EPS | -1.56 | P/E | N/A | Forward P/E | -14.33 |
| Beta | 1.54 | Short Ratio | 10.24 | Inst. Own | 23.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.25 | 200-d Avg | 4.26 | 1yr Est | 16.81 |
RCEL News
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and rais
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst
AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today
AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BAR
Northland Capital Markets analyst Carl Byrnes initiates coverage on AVITA Medical (NASDAQ:RCEL) w
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which missed the analyst
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Hold and raises t
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lower
AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delive
Lake Street analyst Frank Takkinen downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Hold and lo
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independen
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-t
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical", or the "Company"), a
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lower
Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lower
AVITA Medical (NASDAQ:RCEL) lowers FY2025 sales outlook from $100.000 million-$106.000 million to $6
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which missed the analyst
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a leading therapeutic acute wound care company delive
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a leading therapeutic acute wound care company delive
AVITA Medical (NASDAQ:RCEL) affirms FY2025 sales outlook from $100.00 million-$106.00 million to $10
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.53) per share which missed the analyst
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint